Abstract Number: 0328 • ACR Convergence 2022
Predicting Progression from Undifferentiated to Definitive Connective Tissue Diseases: A Systematic Review and Meta-analysis
Background/Purpose: Undifferentiated connective tissue disease (UCTD) encapsulates a broad range of conditions including incomplete forms of systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), some…Abstract Number: 1061 • ACR Convergence 2022
Safety and Tolerability of Aminaphtone in Systemic Sclerosis Patients: A Four-year Follow-up
Background/Purpose: Recent studies proved that aminaphtone is an effective treatment for Raynaud's phenomenon (RP) secondary to systemic sclerosis (SSc). Laser Speckle Contrast Analysis (LASCA) further…Abstract Number: 1183 • ACR Convergence 2022
Functionally Distinct Fibroblast Populations in Systemic Sclerosis Skin Revealed by Explant Tissue Characterization and Single-cell RNAseq
Background/Purpose: Traditional studies of skin fibroblasts in SSc focus on the early "migratory" fibroblast population derived from explant culture of skin biopsies. Single-cell RNAseq has…Abstract Number: 1533 • ACR Convergence 2022
Use of Body Mass Index in Prediction of Interstitial Lung Disease Related to Systemic Sclerosis Revealed by Decision Trees
Background/Purpose: Some gastrointestinal (GI) and nutritional factors are associated with the presence of interstitial lung disease related to systemic sclerosis (SSc-ILD). However, there are many…Abstract Number: 2158 • ACR Convergence 2022
A Decade of Caring for SSc Patients: Do Outcomes Improve? Data from the Leiden CCISS Cohort
Background/Purpose: Combined Care in Systemic Sclerosis (CCISS) is a prospective cohort of patients referred to Leiden University Medical Center for Raynaud's Phenomenon (RP), a suspicion…Abstract Number: 0515 • ACR Convergence 2022
Juvenile Systemic Sclerosis Treatment Practices in an International Cohort and Comparison to Recent SHARE Consensus Guidelines
Background/Purpose: Juvenile systemic scleroderma (jSSc) is an orphan disease with a prevalence of 3 in 1,000,000 children. Currently no medications are licensed for the treatment…Abstract Number: 1062 • ACR Convergence 2022
Lung Magnetic Resonance Imaging in Systemic Sclerosis Associated Interstitial Lung Disease: Potentiality and Comparison with Other Imaging Techniques
Background/Purpose: Interstitial lung disease (ILD) is one of the most severe complications in systemic sclerosis (SSc). The diagnosis and monitoring of ILD is based on…Abstract Number: 1184 • ACR Convergence 2022
Intracellular Calcium Signals Regulate the Pro-fibrotic Phenotype of Scleroderma Fibroblasts via Calcium/calmodulin-dependent Kinase II
Background/Purpose: We performed an in-depth analysis of the involvement of histone reader bromodomain extra-terminal proteins (BETs) in scleroderma (SSc) fibrosis and showed that JQ1, a…Abstract Number: 1536 • ACR Convergence 2022
Progressive Interstitial Lung Disease Is Frequent Also in Late Disease Stages in Systemic Sclerosis Patients from EUSTAR
Background/Purpose: Short disease duration is a well known predictor for progressive systemic sclerosis-associated interstitial lung disease (SSc-ILD), but studies assessing ILD progression in later disease…Abstract Number: 2159 • ACR Convergence 2022
Gastroesophageal Reflux Disease in an Australian Scleroderma Cohort – Associations and Effect of Treatment
Background/Purpose: To investigate the association between gastroesophageal reflux disease (GORD) and interstitial lung disease (ILD) and determine the effect of GORD treatment on survival in…Abstract Number: 0516 • ACR Convergence 2022
Identifying Current Assessment and Treatment Strategies in Juvenile Systemic Sclerosis: An International Effort to Improve Patient Outcomes
Background/Purpose: Juvenile Systemic Sclerosis (jSSc) is an autoimmune and fibrosing disease associated with significant morbidity and mortality risk. Data on treatment is limited and based…Abstract Number: 1063 • ACR Convergence 2022
Assessment of Calcinosis in Portuguese Patients with Systemic Sclerosis – a Multicenter Study
Background/Purpose: Calcinosis is a challenging problem among Systemic Sclerosis (SSc) patients with a reported prevalence of 18-49%. We aim to define the prevalence of clinical…Abstract Number: 1185 • ACR Convergence 2022
Interleukin-11 Promotes Fibrosis Through Classic and Trans-signaling Pathway in Systemic Sclerosis
Background/Purpose: Interleukin-11 (IL-11) was found significantly upregulated in Systemic sclerosis (SSc), the aim of this study is to explore the pathological role of IL-11 and…Abstract Number: 1540 • ACR Convergence 2022
Correlations of Soluble Interleukin-2 Receptor Serum Levels with Markers of Inflammation and Pathological High-sensitivity Troponin T and Its Possible Role as a Predictor of Early Clinical Progress in Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is characterized by chronic inflammation leading to damage of the vascular endothelium and excessive collagen deposition in several target organs. The…Abstract Number: 2167 • ACR Convergence 2022
Autoantibodies in Patients with Early Systemic Sclerosis in the Collaborative National Quality and Efficacy Registry
Background/Purpose: We sought to describe the autoantibody profile of SSc patients with early disease and examine the clinical, laboratory and prognostic features associated with these…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 46
- Next Page »